多发性骨髓瘤新选择:复宏汉霖达雷妥尤单抗皮下剂型获批I期临床

药渡Daily
Feb 13

2026年2月12日——复宏汉霖(2696.HK)宣布,公司自主研发的达雷妥尤单抗生物类似药HLX15皮下注射剂型(HLX15-SC)的I期临床试验申请已正式获得国家药品监督管理局批准,拟用于多发性骨髓瘤的治疗。这标志着继2024年静脉注射剂型I期临床研究成功完成后,复宏汉霖在该重磅抗肿瘤生物类似药项目的开发上再下一城,全面打通“静脉+皮下”双剂型开发路径,为这款全球销售额已逼近百亿美元大关的明星...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10